Intel stock whipsaws ahead of CES Panther Lake debut as 18A chipmaking bet comes due
6 January 2026
2 mins read

Intel stock whipsaws ahead of CES Panther Lake debut as 18A chipmaking bet comes due

New York, January 5, 2026, 17:49 ET — After-hours

  • Intel closed down 0.03% at $39.37 after a sharp intraday reversal.
  • Investors are focused on Intel’s CES update on Panther Lake, its first high-volume chip on the 18A process.
  • Melius Research upgraded Intel to “buy” and lifted its price target to $50, according to a media report.

Intel shares finished nearly flat on Monday and were little changed after the bell, as traders positioned ahead of the company’s CES presentation later in the evening. The stock closed down 0.03% at $39.37. 1

The stakes are tied to Panther Lake, Intel’s next-generation laptop processor aimed at artificial intelligence workloads, which the company is set to detail at CES in Las Vegas. Panther Lake is the first high-volume product built on Intel’s “18A” process — its next chipmaking technology — after the prior Lunar Lake generation relied heavily on Taiwan Semiconductor Manufacturing Co; Intel has also been working to lift manufacturing “yield,” or the share of usable chips per silicon wafer. 2

CES runs January 6-9, and the early-week press events often move PC and chip stocks before the show floor opens. For Intel, any clarity on timing and production ramps matters now because 18A sits at the center of its plan to bring advanced manufacturing back in-house and expand its foundry business — making chips for outside customers. 3

The Intel event is scheduled for 6 p.m. ET and will be led by Jim Johnson, a senior vice president who runs the company’s PC group, Engadget reported. Investors are likely to watch for updates on manufacturing progress and how quickly new designs show up in laptops from major PC makers. 4

Intel stock traded like a headline-driven name on Monday. Shares opened at $41.68, ran up to $42.01, then slid to an intraday low of $39.28 before settling near $39; about 96 million shares changed hands.

A bullish analyst call also fed early optimism. Melius Research analyst Ben Reitzes upgraded Intel to “buy” and set a $50 price target, and he argued the AI trade can persist if chipmakers “deliver AI productivity and usage soars,” Barron’s reported. 5

But the downside scenario is straightforward: if Intel cannot ramp 18A smoothly or if performance claims land softly against competitors’ launches, confidence can fade fast. Any hint that Intel must lean more on outside manufacturing again would pressure the turnaround narrative.

Beyond CES, the next fundamental checkpoint is quarterly results, but Intel’s investor-relations calendar does not currently list an earnings date. Nasdaq’s earnings calendar estimates a late-January report, but the company has not confirmed timing.

Technically, Monday’s $42 high and the retreat back toward $39 leave traders with fresh reference points. A move back through $42 would signal renewed momentum, while slipping under the day’s lows would test how much of the CES optimism is already priced in.

The next catalyst is Intel’s CES presentation at 6 p.m. ET, where investors will look for concrete details on Panther Lake’s rollout and the pace of Intel’s 18A manufacturing ramp.

Stock Market Today

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
New York, Feb 7, 2026, 10:22 EST — Market closed. Eli Lilly and Company shares closed Friday up $37.34, or 3.7%, at $1,058.18. The move came as U.S. regulators sharpened their tone on “compounded” weight-loss drugs — pharmacy-made versions meant for shortages or special patient needs that have morphed into mass-market alternatives. The FDA said it would take action against telehealth firm Hims & Hers over a $49 pill it marketed as a Wegovy-like option, and Lilly said it “applauded” the agency’s action. 1 Why it matters now: obesity and diabetes medicines have become the growth engine for large drugmakers,
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

7 February 2026
Meta closed down 1.3% Friday at $661.46, capping a 6.4% weekly drop as investors questioned heavy AI spending. Amazon and Alphabet also fell after outlining major capital outlays. Meta’s Instagram suffered a brief outage this week. Legal risks persist, with trials involving Meta set for next week in Los Angeles and New Mexico.
Coterra stock slips as natural gas prices slide 5% — what traders watch next
Previous Story

Coterra stock slips as natural gas prices slide 5% — what traders watch next

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears
Next Story

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Go toTop